Eric

INDIANAPOLIS - Both Phase III pivotal trials begin enrollment in May 2009; Reinforces Lilly's commitment to Alzheimer's disease and biotech product research Eli Lilly and Company (NYSE: LLY) today announced it will begin enrolling patients this month in two separate but identical Phase III clinical trials of solanezumab(i), previously referred to as LY2062430, an anti-amyloid beta monoclonal antibody being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer's disease.